{"title":"MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2062","DOIUrl":null,"url":null,"abstract":"Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2014i9.2062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
